Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.
Dawn B Beaulieu, Ashwin N Ananthakrishnan, Christopher Martin...
https://pubmed.ncbi.nlm.nih.gov/28870657/Actively Recruiting
Led by Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa · Updated on 2020-02-21
1750
Participants Needed
73
Research Sites
208 weeks
Total Duration
This research aims to understand the safety of drugs used to treat inflammatory bowel diseases IBD during pregnancy and breastfeeding, focusing on outcomes for both mothers and their children. The study is observational and will follow pregnant women diagnosed with IBD Crohns disease, ulcerative colitis, or unclassified IBD over five years in Spain. It will also track the health and development of their children for up to four years, particularly looking at serious infections and other serious adverse events. Participants are grouped based on their exposure to IBD medications during pregnancy or shortly before conception those treated with biologic drugs, those treated with immunomodulators, and those not exposed to these drugs. Data will be collected at multiple points during pregnancy and after birth, including disease activity and serious adverse events for the mother, and development, infections, and other health events for the children. The study uses questionnaires and regular follow-ups every three months for children until age four. During the study, mothers will provide information through in-person visits and remote contacts, including completing developmental questionnaires for their children yearly. Researchers will gather detailed clinical data at baseline and during each trimester, delivery, and postpartum. The main outcomes measured include rates of serious infections and adverse events during pregnancy and in children up to four years old. The study also assesses developmental status and the risk of malformations or neoplasms in children related to exposure to IBD drugs.
CONDITIONS
Safety of IBD Drugs During Pregnancy and Breastfeeding: Mothers and Babies' Outcomes (DUMBO Registry)
M
María Chaparro, PhDMD
M
María G Donday
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Lead Sponsor
Spanish Agency of Medicines and Health Products
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 28 weeks of gestation (end of second trimester)
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - From enrollment until delivery (approximately 6 to 7 months)
Participants are followed through pregnancy with updates on disease activity, treatments, and any serious adverse events.
4 visits during pregnancy at the end of each trimester and 1 month after delivery
Duration - Up to 4 years after birth
Participants' children are followed up to 4 years of age to monitor development, serious adverse events, infections, and other health outcomes.
Quarterly remote contacts every 3 months and yearly in-person visits for data confirmation
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Dawn B Beaulieu, Ashwin N Ananthakrishnan, Christopher Martin...
https://pubmed.ncbi.nlm.nih.gov/28870657/Geoffrey C Nguyen, Cynthia H Seow, Cynthia Maxwell...
https://pubmed.ncbi.nlm.nih.gov/26688268/Catherine R Rowan, Garret Cullen, Hugh E Mulcahy...
https://pubmed.ncbi.nlm.nih.gov/29045603/Paul A Harris, Robert Taylor, Robert Thielke...
https://pubmed.ncbi.nlm.nih.gov/18929686/Johan Burisch, Natalia Pedersen, Silvja Cukovic-Cavka...
https://pubmed.ncbi.nlm.nih.gov/24252978/Eilhard Mix, Robert Goertsches, Uwe K Zett
https://pubmed.ncbi.nlm.nih.gov/16998762/Mette Julsgaard, Lisbet A Christensen, Peter R Gibson...
https://pubmed.ncbi.nlm.nih.gov/27063728/Heather A Boyd, Saima Basit, Maria C Harpsøe...
https://pubmed.ncbi.nlm.nih.gov/26083614/U Mahadevan, S Vermeire, K Lasch...
https://pubmed.ncbi.nlm.nih.gov/28169436/María Chaparro, María G Donday, Francisco Abad-Santos...
https://pubmed.ncbi.nlm.nih.gov/34158835/Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Lead Sponsor
Spanish Agency of Medicines and Health Products
Collaborating Sponsor